Autoimmune Conditions

Immune Modulation in Autoimmune Conditions

Immunax is an immune-modulating Macrophage Activating Protein (iMAP). The active ingredient Vitamin D Binding Protein Macrophage Activating Factor (VDBP-MAF) plays an important role in regulating the immune system and coordinating the action of innate immune cells. In autoimmune conditions the immune system mistakenly attacks healthy cells and tissues in the body. These include conditions such as:

Rheumatoid arthritis

Systemic lupus erythematosus (lupus)

Inflammatory bowel disease (IBD)

Multiple sclerosis (MS)

Type 1 diabetes mellitus

Hashimoto's thyroiditis

Graves' disease

Psoriasis

iMAP therapy with Immunax has gained attention as a potential therapeutic agent for autoimmune conditions due to its ability to modulate the immune response, regulate overactive immune cells and activate repair and regeneration mechanisms in the body.

Clinical Benefits of Immunax

Modulation of an overactive immune system
Reduction of inflammation and pain
Regulates osteoclasts and promotes bone resorption
Reduced autoimmune symptoms
Increased mitochondrial energy production
Tissue repair and regeneration

How Does It Work?

iMAP therapy is of interest in various diseases involving the immune system due to its ability to counteract the immunosuppressive effects of elevated levels of serum alpha-N-acetylgalactosaminidase (nagalase), an enzyme that blocks the natural synthesis of VDBP-MAF. Nagalase activity is often elevated in patients with autoimmune diseases, which results in immune system dysfunction and abnormal macrophage activity [25].

Macrophages play a crucial role in the immune response and can contribute to the development and progression of autoimmune diseases [47]. Immunax has shown potential in modulating and regulating macrophage activity [12], which indicates potential therapeutic benefits for autoimmune conditions.

Immunax is a Vitamin D Binding Protein Macrophage Activating Factor (VDBP-MAF) exerting its actions through the Vitamin D axis and pathways. Preliminary research indicates it can also impact gene expression in the endocannabinoid system [12].

Through these pathways Immunax may help to modulate the immune system, reduce inflammation and combat inflammatory pain. Aside from the modulation of macrophage activity, iMAP therapy exhibits other biological properties, such as increased mitochondrial energy production, which can support healing and recovery from disease [11].

Potential Indications of Immunax

Multiple Sclerosis (MS)

MS involves autoimmune inflammation and demyelination of the central nervous system. Abnormal interactions between T cells and B cells lead to myelin destruction and neuronal damage. Immunax has shown promise in modulating the immune response and reducing immune system imbalances by regulating T and B cell responses. Studies have indicated positive effects of VDBP-MAF treatment on the rehabilitation of MS patients [15].

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is characterized by chronic inflammation and joint damage. Variations in Vitamin D-binding protein (VDBP) levels have been linked to genetic factors contributing to RA [27]. Immunax exerts its actions through the vitamin D axis and has been shown to modulate osteoclast activity (resident macrophages in the bone) [39] [53]. Immunax may help to rebalance the activity of osteoclasts and osteoblasts, which are responsible for bone and joint repair. Imbalances in the activity of osteoblasts and osteoclasts can contribute to bone loss and joint destruction in RA. Further research is still needed to fully understand the relationship between VDBP-MAF therapy and rheumatoid arthritis.

Thyroid Autoimmune Disorders

Thyroid autoimmune disorders, such as Hashimoto’s thyroiditis and Graves’ disease, involve an immune attack on the thyroid gland. Immunax has shown potential benefits in modulating the immune response and may help to reduce thyroid inflammation in these conditions. Studies have explored VDBP polymorphisms and the associated risk of thyroid autoimmune diseases [27]. Variations in VDBP may influence immune functions and contribute to the development of autoimmune diseases. Further research is still needed to fully understand the specific mechanisms and therapeutic effects of VDBP-MAF replacement therapy in thyroid autoimmune disorders.

Lupus (Systemic Lupus Erythematosus)

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Patients with SLE have been shown to have elevated levels of nagalase (α-N-acetylgalactosaminidase), an enzyme which denatures VDBP and inhibits the production of VDBP-MAF [25]. As a result, the reduced activation of macrophages may contribute to difficulties in clearing harmful immune complexes in patients with SLE. Elevated levels of nagalase could therefore play a role in the development of SLE. iMAP therapy with Immunax may help to alleviate symptoms and restore immune function.

Type 1 Diabetes

Immunax holds potential in modulating the immune response in type 1 diabetes. Studies have indicated an association between VDBP polymorphisms and the risk of type 1 diabetes [26]. Type 1 diabetics have been found to have lower levels of VDBP, which may directly or indirectly lead to the autoimmune destruction of pancreatic β-cells. Furthermore, Vitamin D, VDBP and Vitamin D Receptor (VDR) play a key role in the regulation of glucose metabolism and the development of diabetic neuropathy and associated pain [54]. More research is needed to better determine the potential role of VDBP-MAF therapy in this condition.

Inflammatory Bowel Disease (IBD)

Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, involve chronic inflammation in the gastrointestinal tract. Increasing evidence supports the concept that the vitamin D axis is inherently involved in immune regulation and inflammatory diseases such as IBD [28]. Due to its action on the vitamin D axis, VDBP-MAF has been explored as a potential modulator of immune dysfunction, gastrointestinal dysbiosis, and chronic inflammation in IBD.

A Field of Ongoing Research

It is important to be aware that VDBP-MAF supplementation in autoimmune conditions is still an area of ongoing research. The treatment is considered experimental. Each autoimmune condition has its unique features and complexities, and individual responses to therapy may vary. Therefore, it is crucial for individuals considering Immunax therapy to consult with a qualified healthcare professional and make an informed decision based on the available scientific evidence.